Merck announced today that it has completed the acquisition of Eyebiotech Limited (EyeBio), a clinical-stage ophthalmic biotechnology company, thereby becoming a new wholly-owned subsidiary of Merck.

The addition of EyeBio to Merck's pipeline may ultimately offer new opportunities for the treatment of certain retinal diseases," explained Dr. Dean Y. Li, President of Merck Research Laboratories. Li, President of Merck Research Laboratories.

''We are delighted to welcome the EyeBio team and look forward to working together to advance Restoret for patients in need,'' he added.

EyeBio's lead candidate, Restoret (EYE103), is an investigational tetravalent tri-specific antibody for patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

Based on positive results from an open-label Phase 1b/2a study, Restoret is expected to move into a pivotal Phase 2b/3 trial to assess its potential for the treatment of DME patients in the second half of 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.